{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:33:11Z","timestamp":1777451591752,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.cjca.2015.10.033","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T03:00:44Z","timestamp":1447210844000},"page":"1221.e1-1221.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Kuan-Hsuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Bang","family":"Leu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yuan","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Hsiu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh-Lih","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shing-Jong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Hwa","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2015.10.033_bib1","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","article-title":"Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cjca.2015.10.033_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.10.033_bib3","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI114027","article-title":"Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene","volume":"83","author":"Bernstein","year":"1989","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2015.10.033_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.10.033_bib5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cjca.2015.10.033_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2015.10.033_bib7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cjca.2015.10.033_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2015.10.033_bib9","first-page":"316","article-title":"Anderson-Fabry disease: a cardiomyopathy that can be cured","volume":"52","author":"Anastasakis","year":"2011","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.cjca.2015.10.033_bib10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in fabry disease. Potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.10.033_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ejhf.230","article-title":"Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease","volume":"17","author":"Hollander","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2015.10.033_bib12","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000247278.88077.09","article-title":"Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease","volume":"67","author":"Kaneski","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2015.10.033_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ymgme.2006.04.013","article-title":"Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy","volume":"89","author":"Vedder","year":"2006","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2015.10.033_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10545-006-0360-6","article-title":"Extracellular matrix turnover and disease severity in Anderson-Fabry disease","volume":"30","author":"Shah","year":"2007","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cjca.2015.10.033_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2015.10.033_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cjca.2015.10.033_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/eurheartj\/ehs166","article-title":"Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis","volume":"34","author":"Yousef","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.10.033_bib18","unstructured":"Kim SU. Lysosomal storage diseases: stem cell-based cell- and gene-therapy [e-pub ahead of print]. Cell Transplant."},{"key":"10.1016\/j.cjca.2015.10.033_bib19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.10.033_bib20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Ishii","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2015.10.033_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.cjca.2015.10.033_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2013.09.008","article-title":"Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A)","volume":"426","author":"Liao","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cjca.2015.10.033_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10545-009-1060-9","article-title":"Leukocyte perturbation associated with Fabry disease","volume":"32","author":"Rozenfeld","year":"2009","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cjca.2015.10.033_bib24","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1161\/01.ATV.0000133606.69732.4c","article-title":"Lipid inflammatory mediators in diabetic vascular disease","volume":"24","author":"Natarajan","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2015.10.033_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.plipres.2006.02.003","article-title":"Inflammation and immune regulation by 12\/15-lipoxygenases","volume":"45","author":"Kuhn","year":"2006","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.cjca.2015.10.033_bib26","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2015.10.033_bib27","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/01.CIR.0000165117.71483.0C","article-title":"p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart","volume":"111","author":"Li","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.10.033_bib28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0735-1097(99)00600-2","article-title":"The role of tumor necrosis factor in the pathophysiology of heart failure","volume":"35","author":"Feldman","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.10.033_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1536\/jhj.45.183","article-title":"Interleukin-6 and cardiovascular diseases","volume":"45","author":"Kanda","year":"2004","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.cjca.2015.10.033_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.physiol.65.092101.142249","article-title":"Stress-activated cytokines and the heart: from adaptation to maladaptation","volume":"65","author":"Mann","year":"2003","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.cjca.2015.10.033_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.yjmcc.2010.10.019","article-title":"Immune inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart","volume":"50","author":"Cieslik","year":"2011","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2015.10.033_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.yjmcc.2010.05.005","article-title":"Monocytic fibroblast precursorsmediate fibrosis in angiotensin-II-induced cardiac hypertrophy","volume":"49","author":"Haudek","year":"2010","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2015.10.033_bib33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1152\/ajpheart.01114.2010","article-title":"CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis","volume":"301","author":"Xu","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"}],"updated-by":[{"DOI":"10.1016\/j.cjca.2016.10.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000}}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15015780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15015780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T20:28:03Z","timestamp":1537216083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X15015780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0828282X15015780"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2015.10.033","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.cjca.2016.10.004","asserted-by":"object"}]},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2015.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}